Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NeuroMetrix (NURO) stocks in Canada

Learn how to easily invest in NeuroMetrix stocks.

NeuroMetrix is a medical instruments & supplies business based in the US. NeuroMetrix stocks (NURO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.7 – a decrease of 16.7% over the previous week. NeuroMetrix employs 20 staff and has a trailing 12-month revenue of around $8.2 million.

How to buy shares in NeuroMetrix

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NURO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NeuroMetrix stock price (NASDAQ:NURO)

Use our graph to track the performance of NURO stocks over time.

NeuroMetrix shares at a glance

Information last updated 2022-01-24.
Latest market close$4.54
52-week range$2.58 - $24.73
50-day moving average $6.08
200-day moving average $7.22
Wall St. target price$50.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.37

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy NeuroMetrix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

NeuroMetrix price performance over time

Historical closes compared with the close of $4.54 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-23) -17.30%
3 months (2021-10-26) -37.72%
6 months (2021-07-26) -74.99%
1 year (2021-01-26) -8.84%
2 years (2020-01-24) -4.42%
3 years (2019-01-25) 382.98%
5 years (2017-01-26) 482.05%

NeuroMetrix financials

Revenue TTM $8.2 million
Gross profit TTM $5.2 million
Return on assets TTM -4.53%
Return on equity TTM -10.84%
Profit margin -19.46%
Book value $3.65
Market capitalisation $31.9 million

TTM: trailing 12 months

NeuroMetrix share dividends

We're not expecting NeuroMetrix to pay a dividend over the next 12 months.

Have NeuroMetrix's shares ever split?

NeuroMetrix's shares were split on a 1:10 basis on 18 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeuroMetrix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for NeuroMetrix shares which in turn could have impacted NeuroMetrix's share price.

NeuroMetrix share price volatility

Over the last 12 months, NeuroMetrix's shares have ranged in value from as little as $2.58 up to $24.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuroMetrix's is 2.8844. This would suggest that NeuroMetrix's shares are significantly more volatile than the average for this exchange and represent a higher risk.

NeuroMetrix overview

NeuroMetrix, Inc. , a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site